Exploring Uncertainty in Cost-Effectiveness Analysis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  PharmacoEconomics (Auckland)

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Computer Science, Economics

• Identifiers
  DOI 10.2165/00019053-200826090-00008PMID 18767898
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NICE’s 2008 Methods Guide

  2012cited by this paper
• Use of Indirect and Mixed Treatment Comparisons for Technology Assessment

  2012cited by this paper
• Subgroups and Heterogeneity in Cost-Effectiveness Analysis

  2012cited by this paper
• Dangerous omissions: the consequences of ignoring decision uncertainty.

  2011cited by this paper
• Assessment and Propagation of Model Uncertainty

  2011cited by this paper
• Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions.

  2010cited by this paper
• EXPECTED VALUE OF SAMPLE INFORMATION IN

  2009cited by this paper
• Dimensions of Design Space: A Decision-Theoretic Approach to Optimal Research Design

  2009cited by this paper
• Value based pricing for NHS drugs: an opportunity not to be missed?

  2008cited by this paper
• The Half-Life of Truth: What Are Appropriate Time Horizons for Research Decisions?

  2008cited by this paper
• Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms

  2007cited by this paper
• Eliciting and using expert opinions about dropout bias in randomized controlled trials

  2007cited by this paper
• Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research

  2007cited by this paper
• Eliciting expert opinion for economic models: an applied example.

  2007cited by this paper
• Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses

  2007cited by this paper
• Expected value of sample information for Weibull survival data.

  2007cited by this paper
• Expected value of information and decision making in HTA.

  2007cited by this paper
• Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence

  2007cited by this paper
• Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA.

  2007cited by this paper
• Defining and characterising structural uncertainty in decision analytic models

  2006cited by this paper
• Drug eluting stents

  2006cited by this paper
• Evidence synthesis, parameter correlation and probabilistic sensitivity analysis.

  2006cited by this paper
• Uncertain Judgements: Eliciting Experts' Probabilities

  2006cited by this paper
• Multiparameter evidence synthesis in epidemiology and medical decision‐making: current approaches

  2006cited by this paper
• Probabilistic analysis and computationally expensive models: Necessary and required?

  2006cited by this paper
• Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.

  2005cited by this paper
• Gaussian Process Modeling in Conjunction with Individual Patient Simulation Modeling: A Case Study Describing the Calculation of Cost-Effectiveness Ratios for the Treatment of Established Osteoporosis

  2004cited by this paper
• Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.

  2004cited by this paper
• Value of Information Literature Analysis: A Review of Applications in Health Risk Management

  2004cited by this paper
• Expected Value of Sample Information Calculations in Medical Decision Modeling

  2004cited by this paper
• Truth Survival in Clinical Research: An Evidence-Based Requiem?

  2002cited by this paper
• Representing uncertainty: the role of cost-effectiveness acceptability curves.

  2001cited by this paper
• Incorporating option values into the economic evaluation of health care technologies.

  2000cited by this paper
• Testing the Validity of Cost-Effectiveness Models

  2000cited by this paper
• Statistical Decision Theory

  2000cited by this paper
• The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies.

  1999cited by this paper
• Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective.

  1999cited by this paper
• Sensitivity Analysis and the Expected Value of Perfect Information

  1998cited by this paper
• Net Health Benefits

  1998cited by this paper
• Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis

  1998cited by this paper
• Carrier screening for cystic fibrosis: costs and clinical outcomes.

  1998cited by this paper
• An Introduction to Markov Modelling for Economic Evaluation

  1998cited by this paper
• Going beyond the single number: Using probabilistic risk assessment to improve risk management

  1996cited by this paper
• Model uncertainty, data mining and statistical inference

  1995cited by this paper
• Costs, effects and C/E-ratios alongside a clinical trial.

  1994cited by this paper
• On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses

  1991cited by this paper

• Recommendations for the use of early cost-effectiveness analysis to inform the health technology development process with an application to cutaneous squamous cell carcinoma

  2025cites this paper
• High-flow nasal cannula therapy versus continuous positive airway pressure for non-invasive respiratory support in paediatric critical care: the FIRST-ABC RCTs.

  2025cites this paper
• Co-designing a Structured Expert Elicitation with Clinicians to Enhance Health Care Decision Making in Exercise Oncology

  2025cites this paper
• Using risk prediction models to inform personalized, cost-effective treatment recommendations

  2025cites this paper
• An Early-Stage Decision-Analytic Health Economic Model of Above Cuff Vocalization: What Do We Know and What Do We Need to Resolve?

  2025cites this paper
• Impact of Patient Provider Support Agency model in National Tuberculosis Elimination Program in India (Preprint)

  2025cites this paper
• How many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses?

  2024cites this paper
• 'Managing values' in health economics modelling: Philosophical and practical considerations.

  2024cites this paper
• Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators

  2024cites this paper
• Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia

  2024cites this paper
• A methodological guide for implementing and interpreting results of probabilistic analysis

  2024cites this paper
• A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence

  2024cites this paper
• Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments

  2024cites this paper
• Net Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty

  2024cites this paper
• Economic analyses in cardiac electrophysiology: from clinical efficacy to cost utility

  2024cites this paper
• Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework

  2024cites this paper
• Cost-effectiveness Analysis of Pharmacological Treatment for Adult Kidney Transplant Recipients in Colombia.

  2024cites this paper
• Response to “UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS: GUIDANCE OF THE HTAi-DIA WORKING GROUP”

  2023cites this paper
• Applying clinical decision aids for the assessment and management of febrile infants presenting to emergency care in the UK and Ireland: Febrile Infant Diagnostic Assessment and Outcome (FIDO) Study protocol

  2023cites this paper
• Economic evaluations of non-communicable diseases conducted in Sub-Saharan Africa: a critical review of data sources

  2023cites this paper
• Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework

  2023influential citation
• When should global health actors prioritise more uncertain interventions?

  2023cites this paper
• Economic evaluation of breast MRI in screening - a systematic review and basic approach to cost-effectiveness analyses

  2023cites this paper
• Value of Information Analysis of a Web-Based Self-Management Intervention for Chronic Obstructive Pulmonary Disease

  2023cites this paper
• Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades

  2022cites this paper
• How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea

  2022cites this paper
• Management accounting and the concepts of exploratory data analysis and unsupervised machine learning: a literature study and future directions

  2022cites this paper
• A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis

  2022influential citation
• Eliciting uncertainty for complex parameters in model-based economic evaluations: quantifying a temporal change in the treatment effect

  2022cites this paper
• Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey.

  2022cites this paper
• Methods for Extrapolating Survival Analyses for the Economic Evaluation of Advanced Therapy Medicinal Products

  2022cites this paper
• Risk of ageism in the use of cost-effectiveness thresholds in the recommendations of the national commission for incorporation of technologies in the Brazilian Unified Health System

  2022cites this paper
• Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches

  2022cites this paper
• Cost-effectiveness of camrelizumab versus chemotherapy for the treatment of advanced or metastatic esophageal squamous cell carcinoma.

  2021cites this paper
• Framework for the development and evaluation of complex interventions: gap analysis, workshop and consultation-informed update

  2021cites this paper
• Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India

  2021cites this paper
• Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

  2021cites this paper
• Generating, Presenting, and Interpreting Cost-Effectiveness Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better Practice

  2021cites this paper
• Self-admission in the treatment of eating disorders: an analysis of healthcare resource reallocation

  2021cites this paper
• Cost-effectiveness of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore

  2021cites this paper
• Reduced exposure to vasopressors through permissive hypotension to reduce mortality in critically ill people aged 65 and over: the 65 RCT.

  2021cites this paper
• Cost-effectiveness of Emollients in the Prevention of Relapse among French Patients with Atopic Dermatitis

  2021cites this paper
• Preoperative comprehensive geriatric assessment and optimisation prior to elective arterial vascular surgery: a health economic analysis.

  2021cites this paper
• Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study.

  2021cites this paper
• Calculating and Interpreting ICERs and Net Benefit

  2020cites this paper
• Health-economic evaluations of person-centred care

  2020cites this paper
• A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes

  2020cites this paper
• Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions

  2020cites this paper
• Cost-Effectiveness of CABG plus Mitral-Valve Repair vs CABG Alone for Moderate Ischemic Mitral Regurgitation

  2020cites this paper
• A Computationally Efficient Method for Probabilistic Parameter Threshold Analysis for Health Economic Evaluations

  2020cites this paper
• Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation.

  2020cites this paper
• Artificial neural network metamodel for sensitivity analysis in a total hip replacement health economic model

  2020cites this paper
• Why it’s Time to Abandon the ICER

  2020cites this paper
• Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model

  2020cites this paper
• Subcategorizing the Expected Value of Perfect Implementation to Identify When and Where to Invest in Implementation Initiatives

  2020cites this paper
• Cost utility of a pharmacist-led minor ailment service compared with usual pharmacist care

  2020cites this paper
• The Application and Implications of Novel Deterministic Sensitivity Analysis Methods

  2020cites this paper
• Challenges in synthesising cost-effectiveness estimates

  2020cites this paper
• Cost-Effectiveness of Vitamin D Supplementation in Pregnant Woman and Young Children in Preventing Rickets: A Modeling Study

  2020cites this paper
• Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models

  2019cites this paper
• The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function

  2019cites this paper
• Evaluations of Morphine and Fentanyl for Mechanically Ventilated Patients With Respiratory Disorders in Intensive Care: A Systematic Review of Methodological Trends and Reporting Quality.

  2019cites this paper
• A nurse-led, preventive, psychological intervention to reduce PTSD symptom severity in critically ill patients: the POPPI feasibility study and cluster RCT

  2019cites this paper
• A Framework to Prioritise Health Research Proposals for Funding: Integrating Value for Money

  2019cites this paper
• Effective healthcare cost containment policies. Using the Netherlands as a case study

  2019cites this paper
• Multivariable and Structural Uncertainty Analyses for Cost-Effectiveness Estimates: Back to the Future.

  2019cites this paper
• The importance of accounting for the uncertainty around the preference-based health-related quality-of-life measures value sets: a systematic review

  2019cites this paper
• The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness.

  2019cites this paper
• "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.

  2019cites this paper
• Cost-effectiveness analyses of genetic and genomic diagnostic tests

  2018cites this paper
• Cost-Effectiveness of Mitral Valve Repair Versus Replacement for Severe Ischemic Mitral Regurgitation: A Randomized Clinical Trial From the Cardiothoracic Surgical Trials Network

  2018cites this paper
• Cost-Effectiveness of a Multifaceted Podiatry Intervention for the Prevention of Falls in Older People: The REducing Falls with Orthoses and a Multifaceted Podiatry Intervention Trial Findings

  2018cites this paper
• Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality.

  2018cites this paper
• This is a repository copy of Cost-Effectiveness of a Multifaceted Podiatry Intervention for the Prevention of Falls in Older People: The REducing Falls with Orthoses and a Multifaceted Podiatry Intervention Trial Findings

  2018cites this paper
• Cost effectiveness of mHealth intervention by community health workers for reducing maternal and newborn mortality in rural Uttar Pradesh, India

  2018cites this paper
• How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework

  2018cites this paper
• Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses

  2018cites this paper
• Economic evaluation of Zepatier for the management of HCV in the Italian scenario

  2018cites this paper
• Cost-effectiveness of a multifaceted podiatry intervention for the prevention of falls in older people: The 3 REFORM trial findings 4

  2018cites this paper
• The economic case for precision medicine

  2018cites this paper
• How lack of information hampers decision making in ophthalmology

  2017cites this paper
• Trends and health economic aspects of service delivery of glaucoma

  2017cites this paper
• Health technology assessment of medical devices during development

  2017influential citation
• Cost Effectiveness Analysis

  2017cites this paper
• Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.

  2017cites this paper
• Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer

  2017cites this paper
• Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models

  2017cites this paper
• Clinical effectiveness and cost-effectiveness of a multifaceted podiatry intervention for falls prevention in older people: a multicentre cohort randomised controlled trial (the REducing Falls with ORthoses and a Multifaceted podiatry intervention trial).

  2017cites this paper
• Cost-Effectiveness Analysis of the Use of a Prophylactic Antibiotic for Patients Undergoing Lower Limb Amputation due to Diabetes or Vascular Illness in Colombia.

  2017cites this paper
• Introduction to Statistics and Modeling Methods Applied in Health Economics

  2017cites this paper
• Cost-Effectiveness of Endoscopic Versus Microscopic Transsphenoidal Surgery for Pituitary Adenoma.

  2017cites this paper
• Multiple Effects Cost-Effectiveness Analysis in Cost-Disutility Space

  2017cites this paper
• Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.

  2017cites this paper
• A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses.

  2017cites this paper
• Beyond the Individual: Evaluating Community-Based Health Promotion and Prevention Strategies and Palliative Care Domains of Effect

  2017cites this paper
• Cost-Utility of Partially Implantable Active Middle Ear Implants for Sensorineural Hearing Loss: A Decision Analysis.

  2017cites this paper
• Cost-effectiveness analysis of sedatives in the management of neonates undergoing mechanical ventilation in the intensive care setting in Qatar

  2017cites this paper
• The value of information for woodland management: updating a state–transition model

  2017cites this paper
• Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.

  2017cites this paper
• Commercial viability of medical devices using Headroom and return on investment calculation

  2016cites this paper